Metabolic reprogramming in osteosarcoma

Shi, Yulu; Yue, Xueping; Luo, Qing

doi:10.1002/pdi3.18

Cited by 2 publications

(2 citation statements)

References 144 publications

(289 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In osteosarcoma, the reprogramming of metabolic activity aided its progression making it more aggressive and was reported to even enhance drug resistance [154]. Common metabolic alterations involve glycolysis, amino acid, lipid production, and the TCA cycle [155].…”

Section: Melatonin and Cancer Metabolismmentioning

confidence: 99%

Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations

Al-Ansari,

Samuel,

Büsselberg

2024

Biomolecules

View full text Add to dashboard Cite

Melatonin, an endogenous neurohormone produced by the pineal gland, has received increased interest due to its potential anti-cancer properties. Apart from its well-known role in the sleep–wake cycle, extensive scientific evidence has shown its role in various physiological and pathological processes, such as inflammation. Additionally, melatonin has demonstrated promising potential as an anti-cancer agent as its function includes inhibition of tumorigenesis, induction of apoptosis, and regulation of anti-tumor immune response. Although a precise pathophysiological mechanism is yet to be established, several pathways related to the regulation of cell cycle progression, DNA repair mechanisms, and antioxidant activity have been implicated in the anti-neoplastic potential of melatonin. In the current manuscript, we focus on the potential anti-cancer properties of melatonin and its use in treating and managing pediatric osteosarcoma. This aggressive bone tumor primarily affects children and adolescents and is treated mainly by surgical and radio-oncological interventions, which has improved survival rates among affected individuals. Significant disadvantages to these interventions include disease recurrence, therapy-related toxicity, and severe/debilitating side effects that the patients have to endure, significantly affecting their quality of life. Melatonin has therapeutic effects when used for treating osteosarcoma, attributed to its ability to halt cancer cell proliferation and trigger apoptotic cell death, thereby enhancing chemotherapeutic efficacy. Furthermore, the antioxidative function of melatonin alleviates harmful side effects of chemotherapy-induced oxidative damage, aiding in decreasing therapeutic toxicities. The review concisely explains the many mechanisms by which melatonin targets osteosarcoma, as evidenced by significant results from several in vitro and animal models. Nevertheless, if further explored, human trials remain a challenge that could shed light and support its utility as an adjunctive therapeutic modality for treating osteosarcoma.

show abstract

Section: Melatonin and Cancer Metabolismmentioning

confidence: 99%

Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations

Al-Ansari,

Samuel,

Büsselberg

2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…The main source of NADPH in the cell is the pentose phosphate pathway (PPP) [137] with the rate-limiting enzyme glucose-6-phosphate dehydrogenase (G6PD) [138]. It is also produced secondarily by malic enzyme (ME), isocitrate dehydrogenase (IDH), nicotinamide nucleotide transhydrogenase (NNT) [139][140][141][142][143][144], and NAD+ kinase (NADK) [145].…”

Section: Nadp + /Nadphmentioning

confidence: 99%

Lipid Peroxidation-Related Redox Signaling in Osteosarcoma

Borović Šunjić,

Jaganjac,

Vlainić

et al. 2024

IJMS

View full text Add to dashboard Cite

Oxidative stress and lipid peroxidation play important roles in numerous physiological and pathological processes, while the bioactive products of lipid peroxidation, lipid hydroperoxides and reactive aldehydes, act as important mediators of redox signaling in normal and malignant cells. Many types of cancer, including osteosarcoma, express altered redox signaling pathways. Such redox signaling pathways protect cancer cells from the cytotoxic effects of oxidative stress, thus supporting malignant transformation, and eventually from cytotoxic anticancer therapies associated with oxidative stress. In this review, we aim to explore the status of lipid peroxidation in osteosarcoma and highlight the involvement of lipid peroxidation products in redox signaling pathways, including the involvement of lipid peroxidation in osteosarcoma therapies.

show abstract

Metabolic reprogramming in osteosarcoma

Cited by 2 publications

References 144 publications

Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations

Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations

Lipid Peroxidation-Related Redox Signaling in Osteosarcoma

Contact Info

Product

Resources

About